Latest glioblastoma multiforme Stories
50% of Patients Treated with Mipsagargin had No Tumor Growth at Four Months SAN ANTONIO, Sept. 8, 2014 /PRNewswire/ -- GenSpera, Inc.
Research takes another step closer to clinical trials. Chicago, IL (PRWEB) September 04, 2014 The American Brain Tumor Association (ABTA) Discovery Grant
VANCOUVER, British Columbia and MENLO PARK, Calif., Sept.
Designation of High Unmet Medical Need allows for accelerated review of regulatory submissions in Japan, the second largest medical device market in the world ST.
Global research initiative to investigate long-term glioblastoma survivors. Chicago, IL (PRWEB) September 03, 2014 The American Brain Tumor Association
Mipsagargin Contains New Pre-Stem "Gargin," Defining a Unique Pharmacologic Group Unlike Any Drug Currently or Previously on the Market SAN ANTONIO, Sept.
-- Brings Total Number of DelMar's Patents Covering VAL-083 to Two U.S. Patents and One International Patent -- VANCOUVER, British Columbia and MENLO PARK, Calif., Sept.
Doctors at Atlantic NeuroSurgical Specialists (ANS) have added a new and innovative form of therapy to their treatment arsenal in the battle against glioblastoma multiforme (GBM).
Investor update call to be held Tuesday, September 2 VANCOUVER, British Columbia and MENLO PARK, Calif., Aug.
SAN ANTONIO, Aug. 28, 2014 /PRNewswire/ -- GenSpera, Inc.
- A member of the swell-mob; a genteelly clad pickpocket. Sometimes mobsman.